Welcome to our dedicated page for Inari Medical news (Ticker: NARI), a resource for investors and traders seeking the latest updates and insights on Inari Medical stock.
Inari Medical, Inc. (NASDAQ: NARI) is a leading medical device company dedicated to developing innovative solutions for the interventional treatment of vascular thrombi and emboli. The company's mission centers on improving the lives of patients suffering from venous and other related diseases through the design and production of advanced medical devices.
Inari Medical's product portfolio includes several key devices:
- ClotTriever: Designed for the removal of clots from peripheral blood vessels, primarily treating patients with deep vein thrombosis (DVT).
- FlowTriever System: Used for the treatment of pulmonary embolism (PE).
- InThrill System: Aimed at treating small vessel thrombosis.
- LimFlow System: Another innovative solution recently added to their portfolio through acquisition.
The company operates extensively within the United States but also generates significant revenue from international markets. Inari Medical's dedication to clinical research and patient education is evident in their continuous efforts to generate high-quality clinical data to support their products.
In recent news, Inari Medical announced the PEERLESS II RCT, a major clinical study involving up to 1,200 patients. This study aims to influence global guidelines for treating intermediate-risk PE patients. Inari's fourth-quarter financial results showed a substantial revenue increase, driven by the strong adoption of their procedures, new product launches, and global commercial expansion. The company reported $132.1 million in revenue for Q4 2023, marking a 22.6% increase year-over-year.
Additionally, Inari Medical has undertaken significant legal action to protect its intellectual property. The company filed a patent infringement lawsuit against Imperative Care, Inc. and Truvic Medical, Inc., seeking injunctive relief and damages for infringement on eight of its patents.
Guided by principles such as putting patients first and fostering innovation, Inari Medical continues to advance its mission of establishing its treatments as the standard of care for venous thromboembolism and beyond.
Inari Medical, Inc. (NASDAQ: NARI) will report its Q1 2023 financial results on May 3, 2023. The company focuses on innovative medical devices for treating venous diseases. A conference call and webcast will be held at 1:30 PM PT / 4:30 PM ET on the same day to discuss these results and recent company highlights. Interested parties can access the call via telephone or through the investor relations website. Inari Medical is committed to improving patient outcomes through education, clinical research, and innovative solutions for unmet health needs. The company aims to establish its treatments as the standard of care for venous thromboembolism.
FAQ
What is the current stock price of Inari Medical (NARI)?
What is the market cap of Inari Medical (NARI)?
What does Inari Medical, Inc. specialize in?
What are the key products in Inari Medical's portfolio?
Where does Inari Medical generate most of its revenue?
What recent clinical study has Inari Medical announced?
How did Inari Medical perform financially in the fourth quarter of 2023?
What is Inari Medical's approach to innovation?
Who should investors contact for more information?
What legal actions has Inari Medical recently taken?
What are Inari Medical's guiding principles?
How can interested parties access Inari Medical's live events?
